{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:52:32Z","timestamp":1793649152383,"version":"4.5.1"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40265-026-02347-5","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:24:49Z","timestamp":1785227089000},"page":"1471-1487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Emerging Strategies Targeting the PI3K\/AKT\/mTOR Pathway in HR+\/HER2\u2013 Advanced Breast Cancer"],"prefix":"10.1007","volume":"86","author":[{"given":"Lan","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Canning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Sakach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almeera","family":"Lateef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Kamga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minaam","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kalinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipra","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"1","key":"2347_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2347_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74(6):477\u201395. https:\/\/doi.org\/10.3322\/caac.21863.","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"2347_CR3","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1158\/1078-0432.Ccr-22-0305","volume":"28","author":"M Cristofanilli","year":"2022","unstructured":"Cristofanilli M, Rugo HS, Im SA, et al. Overall survival with palbociclib and fulvestrant in women with HR+\/HER2- ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study. Clin Cancer Res. 2022;28(16):3433\u201342. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-0305.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"2347_CR4","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/jco.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875\u201384. https:\/\/doi.org\/10.1200\/jco.2017.73.7585.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2347_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1911149.","journal-title":"N Engl J Med"},{"issue":"4_Suppl.","key":"2347_CR6","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Sabcs18-pd2-05","volume":"79","author":"P Neven","year":"2019","unstructured":"Neven P, Petrakova K, Val Bianchi G, et al. Abstract PD2-05: biomarker analysis by baseline circulating tumor DNA alterations in the MONALEESA-3 study. Cancer Res. 2019;79(4_Suppl.):PD2-05. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs18-pd2-05.","journal-title":"Cancer Res"},{"issue":"8","key":"2347_CR7","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/1078-0432.Ccr-21-3276","volume":"28","author":"SM Tolaney","year":"2022","unstructured":"Tolaney SM, Toi M, Neven P, et al. Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant. Clin Cancer Res. 2022;28(8):1500\u20136. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3276.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2347_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"S-A Im","year":"2019","unstructured":"Im S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1903765.","journal-title":"N Engl J Med"},{"issue":"17","key":"2347_CR9","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner NC, Im S-A, Saura C, et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2024;391(17):1584\u201396. https:\/\/doi.org\/10.1056\/NEJMoa2404625.","journal-title":"N Engl J Med"},{"issue":"4","key":"2347_CR10","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/s1470-2045(23)00676-9","volume":"25","author":"IM Browne","year":"2024","unstructured":"Browne IM, Andr\u00e9 F, Chandarlapaty S, Carey LA, Turner NC. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 2024;25(4):e139\u201351. https:\/\/doi.org\/10.1016\/s1470-2045(23)00676-9.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2347_CR11","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1001\/jamaoncol.2016.0891","volume":"2","author":"SZ Millis","year":"2016","unstructured":"Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19\u202f784 diverse solid tumors. JAMA Oncol. 2016;2(12):1565\u201373. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0891.","journal-title":"JAMA Oncol"},{"issue":"5","key":"2347_CR12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1158\/1535-7163.MCT-13-0865","volume":"13","author":"C Fritsch","year":"2014","unstructured":"Fritsch C, Huang A, Chatenay-Rivauday C, et al. Characterization of the novel and specific PI3K\u03b1 inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014;13(5):1117\u201329.","journal-title":"Mol Cancer Ther"},{"key":"2347_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102861","volume":"132","author":"C Hao","year":"2025","unstructured":"Hao C, Wei Y, Meng W, Zhang J, Yang X. PI3K\/AKT\/mTOR inhibitors for hormone receptor-positive advanced breast cancer. Cancer Treat Rev. 2025;132:102861. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102861.","journal-title":"Cancer Treat Rev"},{"issue":"20","key":"2347_CR14","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andre","year":"2019","unstructured":"Andre F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1813904.","journal-title":"N Engl J Med"},{"issue":"5857","key":"2347_CR15","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1126\/science.1150799","volume":"318","author":"CH Huang","year":"2007","unstructured":"Huang CH, Mandelker D, Schmidt-Kittler O, et al. The structure of a human p110alpha\/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science. 2007;318(5857):1744\u20138. https:\/\/doi.org\/10.1126\/science.1150799.","journal-title":"Science"},{"issue":"1","key":"2347_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6.","journal-title":"Mol Cancer"},{"issue":"8","key":"2347_CR17","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.Can-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu MT, Palafox M, Asghar U, et al. Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 2016;76(8):2301\u201313. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-0728.","journal-title":"Cancer Res"},{"issue":"4","key":"2347_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/2159-8290.Cd-11-0101","volume":"1","author":"TW Miller","year":"2011","unstructured":"Miller TW, Balko JM, Fox EM, et al. ER\u03b1-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 2011;1(4):338\u201351. https:\/\/doi.org\/10.1158\/2159-8290.Cd-11-0101.","journal-title":"Cancer Discov"},{"issue":"8","key":"2347_CR19","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.Cd-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander SA, Cohen O, Gong X, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 2020;10(8):1174\u201393. https:\/\/doi.org\/10.1158\/2159-8290.Cd-19-1390.","journal-title":"Cancer Discov"},{"issue":"11","key":"2347_CR20","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.Cd-18-0264","volume":"8","author":"B O'Leary","year":"2018","unstructured":"O\u2019Leary B, Cutts RJ, Liu Y, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8(11):1390\u2013403. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0264.","journal-title":"Cancer Discov"},{"issue":"16_Suppl.","key":"2347_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.1041","volume":"42","author":"L Park","year":"2024","unstructured":"Park L, Thompson SL, Roose J, et al. Testing patterns and prevalence of PIK3CA, AKT1, and PTEN alterations among patients (pts) with HR+\/HER2- metastatic breast cancer (mBC) in the US. J Clin Oncol. 2024;42(16_Suppl.):1041. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.1041.","journal-title":"J Clin Oncol"},{"key":"2347_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103334","volume":"162","author":"SR Vitale","year":"2021","unstructured":"Vitale SR, Martorana F, Stella S, et al. PI3K inhibition in breast cancer: identifying and overcoming different flavors of resistance. Crit Rev Oncol Hematol. 2021;162:103334. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103334.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"2347_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16122259","volume":"16","author":"IM Browne","year":"2024","unstructured":"Browne IM, Okines AFC. Resistance to targeted inhibitors of the PI3K\/AKT\/mTOR pathway in advanced oestrogen-receptor-positive breast cancer. Cancers (Basel). 2024;16(12):2259. https:\/\/doi.org\/10.3390\/cancers16122259.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2347_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.Cd-23-0704","volume":"14","author":"A Varkaris","year":"2024","unstructured":"Varkaris A, Fece de la Cruz F, Martin EE, et al. Allosteric PI3K\u03b1 inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Cancer Discov. 2024;14(2):227\u201339. https:\/\/doi.org\/10.1158\/2159-8290.Cd-23-0704.","journal-title":"Cancer Discov"},{"issue":"7538","key":"2347_CR25","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nature13948","volume":"518","author":"D Juric","year":"2015","unstructured":"Juric D, Castel P, Griffith M, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)K\u03b1 inhibitor. Nature. 2015;518(7538):240\u20134. https:\/\/doi.org\/10.1038\/nature13948.","journal-title":"Nature"},{"issue":"7205","key":"2347_CR26","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nature07091","volume":"454","author":"S Jia","year":"2008","unstructured":"Jia S, Liu Z, Zhang S, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008;454(7205):776\u20139. https:\/\/doi.org\/10.1038\/nature07091.","journal-title":"Nature"},{"issue":"22","key":"2347_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/jci180927","volume":"135","author":"N Kumari","year":"2025","unstructured":"Kumari N, Wright SC, Witham CM, et al. USP10\/GSK3\u03b2-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer. J Clin Invest. 2025;135(22):e180927. https:\/\/doi.org\/10.1172\/jci180927.","journal-title":"J Clin Invest"},{"issue":"4","key":"2347_CR28","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s43018-020-0047-1","volume":"1","author":"P Razavi","year":"2020","unstructured":"Razavi P, Dickler MN, Shah PD, et al. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer. 2020;1(4):382\u201393. https:\/\/doi.org\/10.1038\/s43018-020-0047-1.","journal-title":"Nat Cancer"},{"issue":"4","key":"2347_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/sj.bjc.6602970","volume":"94","author":"B Karakas","year":"2006","unstructured":"Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 2006;94(4):455\u20139. https:\/\/doi.org\/10.1038\/sj.bjc.6602970.","journal-title":"Br J Cancer"},{"issue":"8","key":"2347_CR30","doi-asserted-by":"publisher","first-page":"772","DOI":"10.4161\/cbt.3.8.994","volume":"3","author":"KE Bachman","year":"2004","unstructured":"Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004;3(8):772\u20135. https:\/\/doi.org\/10.4161\/cbt.3.8.994.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"2347_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.gpb.2017.02.002","volume":"15","author":"SR McGee","year":"2017","unstructured":"McGee SR, Tibiche C, Trifiro M, Wang E. Network analysis reveals a signaling regulatory loop in the PIK3CA-mutated breast cancer predicting survival outcome. Genomics Proteomics Bioinformatics. 2017;15(2):121\u20139. https:\/\/doi.org\/10.1016\/j.gpb.2017.02.002.","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"24","key":"2347_CR32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.1459","volume":"33","author":"C Van Poznak","year":"2015","unstructured":"Van Poznak C, Somerfield MR, Bast RC, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2015;33(24):2695704. https:\/\/doi.org\/10.1200\/JCO.2015.61.1459.","journal-title":"J Clin Oncol"},{"issue":"27","key":"2347_CR33","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/jco.22.01063","volume":"40","author":"NL Henry","year":"2022","unstructured":"Henry NL, Somerfield MR, Dayao Z, et al. Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2022;40(27):3205\u201321. https:\/\/doi.org\/10.1200\/jco.22.01063.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2347_CR34","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","volume":"32","author":"F Andr\u00e9","year":"2021","unstructured":"Andr\u00e9 F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32(2):208\u201317. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.011.","journal-title":"Ann Oncol"},{"issue":"6","key":"2347_CR35","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1158\/1078-0432.CCR-22-2115","volume":"29","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Raskina K, Schrock AB, et al. Biology and targetability of the extended spectrum of PIK3CA mutations detected in breast carcinoma. Clin Cancer Res. 2023;29(6):1056\u201367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2115.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2347_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01284-9","volume":"22","author":"O Mart\u00ednez-S\u00e1ez","year":"2020","unstructured":"Mart\u00ednez-S\u00e1ez O, Chic N, Pascual T, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 2020;22(1):45. https:\/\/doi.org\/10.1186\/s13058-020-01284-9.","journal-title":"Breast Cancer Res"},{"key":"2347_CR37","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2147\/OTT.S81995","volume":"8","author":"GJ Weiss","year":"2015","unstructured":"Weiss GJ, Hoff BR, Whitehead RP, et al. Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making. Onco Targets Ther. 2015;8:959\u201367. https:\/\/doi.org\/10.2147\/OTT.S81995.","journal-title":"Onco Targets Ther"},{"issue":"10","key":"2347_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140293","volume":"10","author":"G Papaxoinis","year":"2015","unstructured":"Papaxoinis G, Kotoula V, Alexopoulou Z, et al. Significance of PIK3CA mutations in patients with early breast cancer treated with adjuvant chemotherapy: a Hellenic Cooperative Oncology Group (HeCOG) Study. PLoS ONE. 2015;10(10):e0140293. https:\/\/doi.org\/10.1371\/journal.pone.0140293.","journal-title":"PLoS ONE"},{"issue":"1","key":"2347_CR39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13058-025-02055-0","volume":"27","author":"M Chaki","year":"2025","unstructured":"Chaki M, Benrashid M, Puri S, et al. Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations. Breast Cancer Res. 2025;27(1):122. https:\/\/doi.org\/10.1186\/s13058-025-02055-0.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"2347_CR40","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10549-024-07376-w","volume":"207","author":"MA Bhave","year":"2024","unstructured":"Bhave MA, Quintanilha JCF, Tukachinsky H, et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat. 2024;207(3):599\u2013609. https:\/\/doi.org\/10.1007\/s10549-024-07376-w.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2347_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22473-9","volume":"8","author":"V Alvarez-Garcia","year":"2018","unstructured":"Alvarez-Garcia V, Bartos C, Keraite I, et al. A simple and robust real-time qPCR method for the detection of PIK3CA mutations. Sci Rep. 2018;8(1):4290. https:\/\/doi.org\/10.1038\/s41598-018-22473-9.","journal-title":"Sci Rep"},{"issue":"1","key":"2347_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96644-6","volume":"11","author":"J Corn\u00e9","year":"2021","unstructured":"Corn\u00e9 J, Le Du F, Quillien V, et al. Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients. Sci Rep. 2021;11(1):17316. https:\/\/doi.org\/10.1038\/s41598-021-96644-6.","journal-title":"Sci Rep"},{"key":"2347_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1435559","volume":"14","author":"S Smilkou","year":"2024","unstructured":"Smilkou S, Kaklamanis L, Balgouranidou I, et al. Direct comparison of an ultrasensitive real-time PCR assay with droplet digital PCR for the detection of PIK3CA hotspot mutations in primary tumors, plasma cell-free DNA and paired CTC-derived gDNAs. Front Oncol. 2024;14:1435559. https:\/\/doi.org\/10.3389\/fonc.2024.1435559.","journal-title":"Front Oncol"},{"issue":"7","key":"2347_CR44","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/1078-0432.Ccr-15-1745","volume":"22","author":"CX Ma","year":"2016","unstructured":"Ma CX, Luo J, Naughton M, et al. A phase I trial of BKM120 (buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer. Clin Cancer Res. 2016;22(7):1583\u201391. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1745.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2347_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2833","volume":"13","author":"CG Sanchez","year":"2011","unstructured":"Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res. 2011;13(2):R21.","journal-title":"Breast Cancer Res"},{"issue":"7","key":"2347_CR46","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/s1470-2045(17)30376-5","volume":"18","author":"J Baselga","year":"2017","unstructured":"Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(7):904\u201316. https:\/\/doi.org\/10.1016\/s1470-2045(17)30376-5.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2347_CR47","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","volume":"19","author":"A Di Leo","year":"2018","unstructured":"Di Leo A, Johnston S, Lee KS, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(1):87\u2013100. https:\/\/doi.org\/10.1016\/S1470-2045(17)30688-5.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2347_CR48","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.annonc.2020.10.596","volume":"32","author":"S Dent","year":"2021","unstructured":"Dent S, Cort\u00e9s J, Im YH, et al. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Ann Oncol. 2021;32(2):197\u2013207. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.596.","journal-title":"Ann Oncol"},{"issue":"13","key":"2347_CR49","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1016\/j.bmcl.2013.05.007","volume":"23","author":"P Furet","year":"2013","unstructured":"Furet P, Guagnano V, Fairhurst RA, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013;23(13):3741\u20138.","journal-title":"Bioorg Med Chem Lett"},{"issue":"16_Suppl.","key":"2347_CR50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1078","volume":"41","author":"S Chia","year":"2023","unstructured":"Chia S, Neven P, Ciruelos EM, et al. Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-negative, advanced breast cancer: analysis of all 3 cohorts of the BYLieve study. J Clin Oncol. 2023;41(16_Suppl.):1078. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.1078.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2347_CR51","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/s1470-2045(24)00673-9","volume":"25","author":"HS Rugo","year":"2024","unstructured":"Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2024;25(12):e629\u201338. https:\/\/doi.org\/10.1016\/s1470-2045(24)00673-9.","journal-title":"Lancet Oncol"},{"issue":"16_Suppl.","key":"2347_CR52","doi-asserted-by":"publisher","first-page":"TPS1109","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1109","volume":"40","author":"MD Laurentiis","year":"2022","unstructured":"Laurentiis MD, Costa L, Gligorov J, et al. EPIK-B5: a phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on\/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4\/6 inhibitor (CDK4\/6i). J Clin Oncol. 2022;40(16_Suppl.):TPS1109\u2013TPS1109. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS1109.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2347_CR53","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1158\/2159-8290.Cd-21-0072","volume":"12","author":"KW Song","year":"2022","unstructured":"Song KW, Edgar KA, Hanan EJ, et al. RTK-dependent inducible degradation of mutant PI3K\u03b1 drives GDC-0077 (inavolisib) efficacy. Cancer Discov. 2022;12(1):204\u201319. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0072.","journal-title":"Cancer Discov"},{"issue":"4_Suppl.","key":"2347_CR54","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Sabcs20-pd1-02","volume":"81","author":"PL Bedard","year":"2021","unstructured":"Bedard PL, Jhaveri K, Cervantes A, et al. Abstract PD1-02: a phase I\/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive\/HER2-negative metastatic breast cancer (HR+\/HER2- mBC). Cancer Res. 2021;81(4_Suppl.):PD1-02. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs20-pd1-02.","journal-title":"Cancer Res"},{"issue":"4_Suppl.","key":"2347_CR55","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Sabcs19-p3-11-23","volume":"80","author":"K Edgar","year":"2020","unstructured":"Edgar K, Hong R, Song K, et al. Abstract P3-11-23: GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models. Cancer Res. 2020;80(4_Suppl.):P3-11-23. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs19-p3-11-23.","journal-title":"Cancer Res"},{"issue":"4_Suppl.","key":"2347_CR56","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Sabcs19-p1-19-46","volume":"80","author":"K Jhaveri","year":"2020","unstructured":"Jhaveri K, Kalinsky K, Bedard P, et al. Abstract P1-19-46: s phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+\/HER2- breast cancer. Cancer Res. 2020;80(4_Suppl.):P1-19-46. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs19-p1-19-46.","journal-title":"Cancer Res"},{"issue":"5_Suppl.","key":"2347_CR57","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Sabcs22-ot3-08-01","volume":"83","author":"D Juric","year":"2023","unstructured":"Juric D, Jhaveri K, Beeram M, et al. Abstract OT3-08-01: a phase 1 trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant allosteric PI3K\u03b1 H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer (aBC) and other solid tumors (PIKASSO-01, trial in progress). Cancer Res. 2023;83(5_Suppl.):OT3-08-01. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs22-ot3-08-01.","journal-title":"Cancer Res"},{"issue":"2","key":"2347_CR58","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1056\/NEJMoa2501796","volume":"393","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Im SA, Saura C, et al. Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2025;393(2):151\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2501796.","journal-title":"N Engl J Med"},{"issue":"16_Suppl.","key":"2347_CR59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1136","volume":"42","author":"D Juric","year":"2024","unstructured":"Juric D, Kalinsky K, Im S-A, et al. INAVO121: phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER-), PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA\/mBC). J Clin Oncol. 2024;42(16_Suppl.):TPS1136. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS1136.","journal-title":"J Clin Oncol"},{"key":"2347_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104979","author":"J Cort\u00e9s","year":"2025","unstructured":"Cort\u00e9s J, Basho RK, Jhaveri K, et al. 408TiP INAVO123: phase III study of first-line (1L) inavolisib\/placebo + a CDK4\/6 inhibitor + letrozole (INAVO\/PBO + CDK4\/6i + LET) in participants (pts) with PIK3CA-mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2-), endocrine-sensitive advanced breast cancer (aBC). ESMO Open. 2025. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104979.","journal-title":"ESMO Open"},{"issue":"9","key":"2347_CR61","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1158\/1078-0432.Ccr-17-2260","volume":"24","author":"U Banerji","year":"2018","unstructured":"Banerji U, Dean EJ, P\u00e9rez-Fidalgo JA, et al. A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers. Clin Cancer Res. 2018;24(9):2050\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2260.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2347_CR62","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1470-2045(19)30817-4","volume":"21","author":"RH Jones","year":"2020","unstructured":"Jones RH, Casbard A, Carucci M, et al. Fulvestrant plus Capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, Phase 2 trial. Lancet Oncol. 2020;21(3):345\u201357. https:\/\/doi.org\/10.1016\/S1470-2045(19)30817-4.","journal-title":"Lancet Oncol"},{"issue":"12_Suppl.","key":"2347_CR63","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.Sabcs24-p3-04-27","volume":"31","author":"F-T Liao","year":"2025","unstructured":"Liao F-T, Qin L, Shea MJ, et al. Abstract P3-04-27: resistance to neratinib in HER2+ breast cancer: mechanistic insights and treatment approaches. Clin Cancer Res. 2025;31(12_Suppl.):P3-04-27. https:\/\/doi.org\/10.1158\/1557-3265.Sabcs24-p3-04-27.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2347_CR64","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1158\/1535-7163.Mct-11-0824-t","volume":"11","author":"BR Davies","year":"2012","unstructured":"Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012;11(4):873\u201387. https:\/\/doi.org\/10.1158\/1535-7163.Mct-11-0824-t.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2347_CR65","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1001\/jamaoncol.2020.6741","volume":"7","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Hong F, McCourt CK, et al. Effect of Capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial. JAMA Oncol. 2021;7(2):271\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6741.","journal-title":"JAMA Oncol"},{"issue":"5","key":"2347_CR66","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/annonc\/mdz086","volume":"30","author":"NC Turner","year":"2019","unstructured":"Turner NC, Alarc\u00f3n E, Armstrong AC, et al. BEECH: a dose-finding run-in followed by a randomised Phase II study assessing the efficacy of AKT inhibitor Capivasertib (AZD5363) combined with Paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Ann Oncol. 2019;30(5):774\u201380. https:\/\/doi.org\/10.1093\/annonc\/mdz086.","journal-title":"Ann Oncol"},{"issue":"22","key":"2347_CR67","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058\u201370. https:\/\/doi.org\/10.1056\/NEJMoa2214131.","journal-title":"N Engl J Med"},{"key":"2347_CR68","unstructured":"US FDA. FDA approves capivasertib with fulvestrant for breast cancer. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-capivasertib-fulvestrant-breast-cancer. Accessed 12 Oct 2025."},{"issue":"9_Suppl.","key":"2347_CR69","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Sabcs23-po2-19-10","volume":"84","author":"H Rugo","year":"2024","unstructured":"Rugo H, Pistilli B, Collins J, et al. Abstract PO2-19-10: CAPItello-292 phase 3: an open-label, randomized study of capivasertib, fulvestrant, and investigator\u2019s choice of CDK4\/6 inhibitor (palbociclib or ribociclib) in HR+\/HER2- advanced breast cancer. Cancer Res. 2024;84(9_Suppl.):PO2-19-10-PO2-19-10. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs23-po2-19-10.","journal-title":"Cancer Res"},{"key":"2347_CR70","unstructured":"AstraZeneca. Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy in advanced or metastatic triple-negative breast cancer. Available frtom: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/update-on-capitello-290-phase-iii-trial.html. Accessed 13 Oct 2025."},{"issue":"1","key":"2347_CR71","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/2159-8290.Cd-16-0512","volume":"7","author":"C Saura","year":"2017","unstructured":"Saura C, Roda D, Rosell\u00f3 S, et al. A first-in-human Phase I study of the ATP-competitive AKT inhibitor Ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors. Cancer Discov. 2017;7(1):102\u201313. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0512.","journal-title":"Cancer Discov"},{"issue":"16_Suppl.","key":"2347_CR72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1111","volume":"41","author":"AFC Okines","year":"2023","unstructured":"Okines AFC, Braybrooke J, MacPherson IR, et al. Randomised open-label phase II study of induction standard of care fulvestrant and CDK4\/6 inhibition with addition of ipatasertib in metastatic ER+\/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM). J Clin Oncol. 2023;41(16_Suppl.):TPS1111. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS1111.","journal-title":"J Clin Oncol"},{"issue":"17_Suppl.","key":"2347_CR73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1005","volume":"43","author":"SKL Chia","year":"2025","unstructured":"Chia SKL, Redfern AD, Ayoub J-PM, et al. A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4\/6 inhibitor and aromatase inhibitor: the CCTG\/BCT MA.40\/FINER study (NCT04650581). J Clin Oncol. 2025;43(17_Suppl.):LBA1005-LBA1005. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA1005.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2347_CR74","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1200\/jco.2011.38.3331","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Lazar AA, Bondarenko I, et al. Randomized Phase III placebo-controlled trial of Letrozole plus oral Temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol. 2013;31(2):195\u2013202. https:\/\/doi.org\/10.1200\/jco.2011.38.3331.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2347_CR75","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1109653.","journal-title":"N Engl J Med"},{"issue":"10","key":"2347_CR76","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","volume":"30","author":"DA Yardley","year":"2013","unstructured":"Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus Exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870\u201384. https:\/\/doi.org\/10.1007\/s12325-013-0060-1.","journal-title":"Adv Ther"},{"issue":"12","key":"2347_CR77","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","volume":"25","author":"M Piccart","year":"2014","unstructured":"Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus Exemestane for hormone-receptor-positive, Human Epidermal Growth Factor Receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25(12):2357\u201362. https:\/\/doi.org\/10.1093\/annonc\/mdu456.","journal-title":"Ann Oncol"},{"issue":"3","key":"2347_CR78","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10549-024-07324-8","volume":"206","author":"R S\u00e1nchez-Bayona","year":"2024","unstructured":"S\u00e1nchez-Bayona R, Lopez de Sa A, Jerez Gilarranz Y, et al. Everolimus plus endocrine therapy beyond CDK4\/6 inhibitors progression for HR+\u2009\/HER2- advanced breast cancer: a real-world evidence cohort. Breast Cancer Res Treat. 2024;206(3):551\u20139. https:\/\/doi.org\/10.1007\/s10549-024-07324-8.","journal-title":"Breast Cancer Res Treat"},{"key":"2347_CR79","doi-asserted-by":"publisher","first-page":"S1676","DOI":"10.1016\/j.annonc.2025.09.026","volume":"36","author":"E Mayer","year":"2025","unstructured":"Mayer E, Tolaney S, Martin M, et al. LBA16 giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2- aBC) previously treated with a CDK4\/6 inhibitor (i): primary results of the phase III evERA BC trial. Ann Oncol. 2025;36:S1676\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.026.","journal-title":"Ann Oncol"},{"issue":"4","key":"2347_CR80","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S1470-2045(24)00034-2","volume":"25","author":"RM Layman","year":"2024","unstructured":"Layman RM, Han HS, Rugo HS, et al. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncol. 2024;25(4):474\u201387. https:\/\/doi.org\/10.1016\/S1470-2045(24)00034-2.","journal-title":"Lancet Oncol"},{"issue":"16_Suppl.","key":"2347_CR81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1118","volume":"41","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Andre F, Cristofanilli M, et al. A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+\/ HER2- advanced breast cancer previously treated with a CDK4\/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1). J Clin Oncol. 2023;41(16_Suppl.):TPS1118. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS1118.","journal-title":"J Clin Oncol"},{"key":"2347_CR82","unstructured":"Celcuity. VIKTORIA-1 pivotal phase 3 topline results from PIK3CA wild-type cohort. Available from: https:\/\/ir.celcuity.com\/wp-content\/uploads\/2025\/07\/Celcuity-Phase-3-VIKTORIA-1-Topline-Results.pdf. Accessed 8 Oct 2025."},{"issue":"6","key":"2347_CR83","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(16)00106-6","volume":"17","author":"IE Krop","year":"2016","unstructured":"Krop IE, Mayer IA, Ganju V, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(6):811\u201321. https:\/\/doi.org\/10.1016\/S1470-2045(16)00106-6.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2347_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1154-8","volume":"21","author":"Y Xing","year":"2019","unstructured":"Xing Y, Lin NU, Maurer MA, et al. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and\/or PTEN loss\/PTEN mutation. Breast Cancer Res. 2019;21(1):78. https:\/\/doi.org\/10.1186\/s13058-019-1154-8.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"2347_CR85","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1016\/s2352-3026(18)30030-9","volume":"5","author":"JR Brown","year":"2018","unstructured":"Brown JR, Hamadani M, Hayslip J, et al. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Lancet Haematol. 2018;5(4):e170\u201380. https:\/\/doi.org\/10.1016\/s2352-3026(18)30030-9.","journal-title":"Lancet Haematol."},{"key":"2347_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2266","volume":"35","author":"AJ Montero","year":"2024","unstructured":"Montero AJ, Giordano A, Jhaveri K, et al. LBA27 first-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients. Ann Oncol. 2024;35:S1220. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2266.","journal-title":"Ann Oncol"},{"issue":"2","key":"2347_CR87","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1158\/2159-8290.Cd-23-0944","volume":"14","author":"A Varkaris","year":"2024","unstructured":"Varkaris A, Pazolli E, Gunaydin H, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3K\u03b1 inhibitor that decouples antitumor activity from hyperinsulinemia. Cancer Discov. 2024;14(2):240\u201357. https:\/\/doi.org\/10.1158\/2159-8290.Cd-23-0944.","journal-title":"Cancer Discov"},{"key":"2347_CR88","doi-asserted-by":"publisher","first-page":"S499","DOI":"10.1016\/j.annonc.2024.08.692","volume":"35","author":"M Fakih","year":"2024","unstructured":"Fakih M, Sohal D, Call JA, et al. <article-title update=\"added\">625P initial results from the phase I, first-in-human study of the covalent, PI3K\u03b1 inhibitor TOS-358 in patients with solid tumors, expressing PI3K\u03b1 mutations or amplifications. Ann Oncol. 2024;35:S499-500. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.692.","journal-title":"Ann Oncol"},{"issue":"12_Suppl.","key":"2347_CR89","doi-asserted-by":"publisher","first-page":"P4-08-24","DOI":"10.1158\/1557-3265.Sabcs24-p4-08-24","volume":"31","author":"A Tolcher","year":"2025","unstructured":"Tolcher A, Varkaris A, Rod\u00f3n J, et al. Abstract P4\u201308-24: AKTive-001: a Phase 1\/1b multiple cohort trial of ALTA2618 in patients with advanced solid tumors with AKT1 E17K nutation (trial in Ppogress). Clin Cancer Res. 2025;31(12_Suppl.):P4-08\u201324. https:\/\/doi.org\/10.1158\/1557-3265.Sabcs24-p4-08-24.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2347_CR90","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1021\/acs.jmedchem.2c01658","volume":"66","author":"GL Burnett","year":"2023","unstructured":"Burnett GL, Yang YC, Aggen JB, et al. Discovery of RMC-5552, a selective bi-steric inhibitor of mTORC1, for the treatment of mTORC1-activated tumors. J Med Chem. 2023;66(1):149\u201369. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01658.","journal-title":"J Med Chem"},{"issue":"12_Suppl.","key":"2347_CR91","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Targ-23-c020","volume":"22","author":"AM Schram","year":"2023","unstructured":"Schram AM, Naqash AR, Haura EB, et al. Abstract C020: first-in-human phase 1\/1b trial of the first-in-class bi-steric mTORC1-selective inhibitor RMC-5552 in patients with advanced solid tumors. Mol Cancer Ther. 2023;22(12_Suppl.):C020. https:\/\/doi.org\/10.1158\/1535-7163.Targ-23-c020.","journal-title":"Mol Cancer Ther"},{"key":"2347_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102520","volume":"71","author":"A Llombart-Cussac","year":"2024","unstructured":"Llombart-Cussac A, P\u00e9rez-Garcia JM, Ruiz Borrego M, et al. Preventing alpelisib-related hyperglycaemia in HR+\/HER2-\/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial. EClinicalMedicine. 2024;71:102520. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102520.","journal-title":"EClinicalMedicine"},{"issue":"5","key":"2347_CR93","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","volume":"18","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Seneviratne L, Beck JT, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017;18(5):654\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(17)30109-2.","journal-title":"Lancet Oncol"},{"key":"2347_CR94","unstructured":"US FDA. FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2\u2013negative, advanced breast cancer. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive. Accessed 2 Dec 2025."},{"issue":"12","key":"2347_CR95","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392(12):1189\u2013202. https:\/\/doi.org\/10.1056\/NEJMoa2410858.","journal-title":"N Engl J Med"},{"issue":"9","key":"2347_CR96","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/jco-24-02086","volume":"43","author":"K Kalinsky","year":"2025","unstructured":"Kalinsky K, Bianchini G, Hamilton E, et al. Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial. J Clin Oncol. 2025;43(9):1101\u201312. https:\/\/doi.org\/10.1200\/jco-24-02086.","journal-title":"J Clin Oncol"},{"issue":"24","key":"2347_CR97","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/jco.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky K, Accordino MK, Chiuzan C, et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol. 2023;41(24):4004\u201313. https:\/\/doi.org\/10.1200\/jco.22.02392.","journal-title":"J Clin Oncol"},{"issue":"13","key":"2347_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137353","volume":"23","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Richmond A, Yan C. Immunomodulatory properties of PI3K\/AKT\/mTOR and MAPK\/MEK\/ERK inhibition augment response to immune checkpoint blockade in melanoma and triple-negative breast cancer. Int J Mol Sci. 2022;23(13):7353.","journal-title":"Int J Mol Sci"},{"key":"2347_CR99","unstructured":"Institute of Cancer Research UK. A trial of ipatasertib in combination with atezolizumab (IceCAP). Available from: https:\/\/clinicaltrials.gov\/study\/NCT03673787. Accessed 28 Apr 2026."},{"key":"2347_CR100","unstructured":"Roche H-L. A study evaluating the efficacy and safety of multiple treatment combinations in patients with metastatic or locally advanced breast vancer (Morpheus-panBC). Available from: https:\/\/clinicaltrials.gov\/study\/NCT03424005#collaborators-and-investigators. Accessed 28 Apr 2026."},{"key":"2347_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2017.07.015","volume":"405","author":"W Guo","year":"2017","unstructured":"Guo W, You X, Wang X, Wang L, Chen Y. A synthetic peptide hijacks the catalytic subunit of class I PI3K to suppress the growth of cancer cells. Cancer Lett. 2017;405:1\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2017.07.015.","journal-title":"Cancer Lett"},{"key":"2347_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217112","volume":"598","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zhang L, He Y, et al. PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. Cancer Lett. 2024;598:217112. https:\/\/doi.org\/10.1016\/j.canlet.2024.217112.","journal-title":"Cancer Lett"},{"issue":"28","key":"2347_CR103","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/jco.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40(28):3246\u201356. https:\/\/doi.org\/10.1200\/jco.22.00338.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2347_CR104","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1706450.","journal-title":"N Engl J Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02347-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02347-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02347-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:03:12Z","timestamp":1788242592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02347-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":104,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2347"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02347-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Elizabeth Sakach: consulting or an advisory role: Stemline, AstraZeneca, and Novartis. Research funding (institution): Pfizer, Puma, Eli Lilly, Rayzebio, and ProDa. Kevin Kalinsky: spouse, stock: EQRX (prior employee) and ADC Therapeutics; consulting fees from Lilly, Novartis, Genentech\/Roche, Gilead, Seattle Genetics, AstraZeneca, Daiichi Sankyo, Puma Biotechnology, Mersana, Menarini Silicon Biosystems, Myovant Sciences, Takeda, Prelude Therapeutics, eFFECTOR Therapeutis, Regor, RayzeBio, Relay Therapuetics, and Merck, and institutional funding from Novartis, Genentech\/Roche, Lilly, Seattle Genetics, AstraZeneca, Daichi Sankyo, and Ascentage, all outside the submitted work. Shipra Gandhi: consulting: Hologic, AstraZeneca, Novartis, MedPage Today, Genentech, Stemline Therapeutics; honorarium: OncLive, Aptitude Health, Clinical Care Options, and PeerView; speaker: Roche. Lan Lei, Madison Canning, Almeera Lateef, Larisa Kamga, and Minaam Abid have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of interest\/Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: SG and KK designed the scope and structure of the review. Data curation: LL collected and organized the literature sources. Writing (original draft): LL, MC, ES, AL, LK, MA. Writing (review and editing): ES, KK, SG.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}